Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44376   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,376 result(s) found. Displaying page 1,933 of 2,219.
    EudraCT Number: 2020-002271-36 Sponsor Protocol Number: MEPIC Start Date*: 2021-03-09
    Sponsor Name:Danderyd Hospital
    Full Title: Mepivacaine for pain relief at insertion of intrauterine contraception (MEPIC) – a triple-blind randomized controlled trial.
    Medical condition: Insertion of intrauterine contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004911-79 Sponsor Protocol Number: AR-01 Start Date*: 2007-10-17
    Sponsor Name:cliniques Universitaires st luc-ucl
    Full Title: Pharmacodynamics of Fondaparinux subcutaneous versus continuous intravenous infusion in critically ill patients with or without vasopressors.
    Medical condition: Thromboprophylaxis to critically ill patients hospitalized in ICU with or without vasopressors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022065-10 Sponsor Protocol Number: SABO-2010-01 Start Date*: 2011-08-02
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within the Swedish Associa...
    Medical condition: Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TN...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004545-91 Sponsor Protocol Number: 59874 Start Date*: 2017-04-13
    Sponsor Name:VU University Medical Center, department of reproductive Medicine
    Full Title: Continuous use of Oral contraceptives as an alternative for long term Pituitary down-regulation with GnRH agonist prior to IVF/ICSI in Endometriosis patients: a randomised controlled trial (COPIE t...
    Medical condition: The research population consists of women with surgically confirmed endometriosis ASRM stage III or IV or endometrioma on transvaginal ultrasound or MRI, scheduled for an IVF/ICSI treatment.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002884-24 Sponsor Protocol Number: Quadruple-P-Study Start Date*: 2017-09-06
    Sponsor Name:AMC
    Full Title: Pessary or Progesterone to Prevent Preterm delivery in women with short cervical length
    Medical condition: preterm birth
    Disease: Version SOC Term Classification Code Term Level
    20.1 10036585 - Pregnancy, puerperium and perinatal conditions 10023555 Labour premature LLT
    20.1 10036585 - Pregnancy, puerperium and perinatal conditions 10023545 Labor premature LLT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036594 Premature birth LLT
    20.1 10036585 - Pregnancy, puerperium and perinatal conditions 10036600 Premature labour PT
    20.1 10036585 - Pregnancy, puerperium and perinatal conditions 10036599 Premature labor LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003560-13 Sponsor Protocol Number: OTL-2016-OTL38-005 Start Date*: 2017-10-18
    Sponsor Name:On Target Laboratories, LLC
    Full Title: A Phase 2, Single dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
    Medical condition: adenocarcinoma lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025044 Lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003581-26 Sponsor Protocol Number: DuoCOMT2008-05-27 Start Date*: 2008-07-18
    Sponsor Name:Dept of Neuroscience, Uppsala University
    Full Title: Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors
    Medical condition: Parkinson's disease (G20.9), advanced, patients presently on Duodopa treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005819-18 Sponsor Protocol Number: DysBot Start Date*: 2009-06-30
    Sponsor Name:Department of Neuroscience, Uppsala University
    Full Title: A comparison of Dysport (100 U/ml) and Botox (100 U/ml) using dose conversion factor 3:1 and 1.7:1 in the treatment of cervical dystonia.
    Medical condition: Cervical dystonia, not multifocal or generalised dystonia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064124 Cervical dystonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004682-39 Sponsor Protocol Number: KFJ-2020-02_NORMOSANG Start Date*: 2020-11-16
    Sponsor Name:Thomayerova nemocnice
    Full Title: Pilot, open-label, monocentric study evaluating safety and clinical effect of application of NORMOSANG® in patients with COVID-19 disease
    Medical condition: Patients with COVID -19 disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001832-27 Sponsor Protocol Number: AT-202 Start Date*: 2023-01-20
    Sponsor Name:Allecra Therapeutics SAS
    Full Title: A Single Group Treatment, Phase 2 study to investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 hours in Male or Female Part...
    Medical condition: Complicated urinary tract infections including acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002851-14 Sponsor Protocol Number: QUIWI Start Date*: 2019-06-21
    Sponsor Name:FUNDACIÓN PETHEMA
    Full Title: A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wi...
    Medical condition: Acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003381-14 Sponsor Protocol Number: AIHBUDPRED1.0 Start Date*: 2020-02-19
    Sponsor Name:Umeå University Hospital
    Full Title: Budesonide versus Prednisolone as Primary Treatment for Autoimmune Hepatitis: An Open-label, Randomized, Prospective Multicenter 12-month Clinical Trial Evaluating Effect and Side-Effects.
    Medical condition: Autoimmune hepatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003425-30 Sponsor Protocol Number: EPX-100-001 Start Date*: 2022-07-27
    Sponsor Name:Epygenix Therapeutics, Inc.
    Full Title: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial)
    Medical condition: Dravet Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000286-23 Sponsor Protocol Number: MS200662_0001 Start Date*: 2016-04-27
    Sponsor Name:Telios Pharma, Inc.
    Full Title: Phase I/II, First in Human, Dose Escalation Trial of TL-895 in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia ...
    Medical condition: B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003900 B-cell lymphomas NEC HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003908 B-cell small lymphocytic lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003810-38 Sponsor Protocol Number: KCP-8602-801 Start Date*: 2021-12-01
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/R...
    Medical condition: High-risk primary refractory MDS patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028535 Myelodysplastic syndrome unclassifiable PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067096 5q minus myelodysplastic syndrome LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067387 Myelodysplastic syndrome transformation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001200-55 Sponsor Protocol Number: 564038 Start Date*: 2015-09-23
    Sponsor Name:Region Östergötland
    Full Title: A single postoperative bisphosphonate infusion to improve patient reported function after hip or knee replacement.
    Medical condition: Prosthetic loosening of hip and knee arthroplasty
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005525-23 Sponsor Protocol Number: 54767414MMY3003 Start Date*: 2014-04-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) BE (Completed) NL (Completed) DK (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001779-15 Sponsor Protocol Number: BGB-A317-Sitravatinib-301 Start Date*: 2022-11-15
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Che...
    Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005109-23 Sponsor Protocol Number: AWC LowE Start Date*: 2009-08-05
    Sponsor Name:Uppsala University Hospital
    Full Title: Low-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound.
    Medical condition: Age/menopause related changes in the artery wall composition after menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    9.1 10051775 Postmenopause LLT
    9.1 10020388 Hormone replacement therapy LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005645-19 Sponsor Protocol Number: 20051130 Start Date*: 2007-09-12
    Sponsor Name:Dept of ped hem/onc
    Full Title: RCT of oral ibuprofen for procedural anxiety, distress and pain in children with cancer
    Medical condition: Pain and anxiety relief before needle insertion in a subcutanously implanted iv port in children with cancer.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jan 26 19:35:50 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA